Ingela Hofverberg appointed as CEO of Atlas Antibodies BU

The Board of Directors of Atlas Antibodies AB has appointed Ingela Hofverberg as the new CEO of Atlas Antibodies AB.

Ingela joined Atlas Antibodies in August 2022 and has held several roles during her tenure, including Chief Transformation & Quality Officer and Chief Financial Officer, and has most recently served as the acting interim CEO of Atlas BU since June 2023.

 

Her dedication, drive, and strong leadership qualities have been evident throughout her tenure, and we are confident that she will continue to drive our company forward with unwavering commitment and passion.

Ingela’s proven track record of transformation and her ability to foster collaboration, make swift decisions, and implement strategic initiatives effectively make her the ideal candidate to lead BU Atlas Antibodies into its next chapter of growth.

“I am thrilled to embark on this new journey as the CEO of BU Atlas Antibodies. I am deeply committed to building upon the strong foundation laid by my predecessors and working closely with each of you to achieve our collective goals. Together, I am confident that we will overcome challenges, seize opportunities, and create a successful company where we all will thrive”, said Ingela.

< | >